Scarica l'app Stockscreener
55.23
4.61%
-2.67
Precedente Chiudi:
$57.90
Aprire:
$58.09
Volume 24 ore:
3.85M
Relative Volume:
3.07
Capitalizzazione di mercato:
$4.59B
Reddito:
$7.50M
Utile/perdita netta:
$-345.91M
Rapporto P/E:
-12.67
EPS:
-4.3602
Flusso di cassa netto:
$-280.51M
1 W Prestazione:
+31.69%
1M Prestazione:
+33.15%
6M Prestazione:
+52.53%
1 anno Prestazione:
+56.99%
Intervallo 1D:
$54.93
$59.00
Intervallo di 1 settimana:
$54.93
$63.95
Portata 52W:
$26.74
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
55.23 | 4.59B | 7.50M | -345.91M | -280.51M | -4.3602 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Sets Date for 2026 Annual Shareholder Meeting - The Globe and Mail
Xenon Pharmaceuticals Inc. Announces 2026 Annual Meeting of Shareholders Details and Notice Procedures - Minichart
Xenon Pharmaceuticals closes $747.5M public offering By Investing.com - Investing.com Australia
Xenon Pharmaceuticals (XENE) sets June 2, 2026 annual shareholder meeting and April 7 record date - Stock Titan
Xenon Pharmaceuticals closes $747.5M public offering - Investing.com South Africa
Xenon Pharmaceuticals closes US $747.5M public offering - Private Capital Journal
Xenon Pharmaceuticals Closes $747.5 Million Public Offering - marketscreener.com
BofA raises Xenon Pharmaceuticals price target on trial success - Investing.com
Xenon Pharmaceuticals Nets $707.7 Million in $57 Share Offering With Pre-Funded Warrants - TradingView
Xenon Pharmaceuticals Announces Closing of $747.5 Million - GlobeNewswire
Xenon Pharmaceuticals launches $500 million stock offering By Investing.com - Investing.com Nigeria
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE) - The Chronicle-Journal
Xenon Pharmaceuticals (NASDAQ: XENE) offers 10.5M shares and 877K warrants for $615M - Stock Titan
Is Xenon Pharmaceuticals (XENE) Pricing Look Compelling After Recent 37% Weekly Share Surge? - simplywall.st
What is HC Wainwright's Estimate for XENE FY2027 Earnings? - MarketBeat
Xenon Pharmaceuticals shares jump 40% after strong Phase 3 seizure trial results - MSN
Xenon Raises $650 Million in Upsized U.S. Equity Offering - The Globe and Mail
Ian Mortimer Sells 11,269 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 270,000 Shares - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells 2,771 Shares of Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $156,706.77 in Stock - MarketBeat
XENE Expands Stock Offering to $650 Million - GuruFocus
Xenon Pharmaceuticals (XENE) CLO sells shares to cover PSU taxes - Stock Titan
Xenon Pharmaceuticals prices $650M public offering at $57/share By Investing.com - Investing.com Australia
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Large Volume Increase on Analyst Upgrade - MarketBeat
Xenon Pharmaceuticals Prices Upsized $650 Million Public Offering of Shares - marketscreener.com
Liquidity Mapping Around (XENE) Price Events - Stock Traders Daily
Xenon Pharmaceuticals (XENE) Upsizes Public Offering to $650 Mil - GuruFocus
Why Xenon Pharmaceuticals (XENE) Is Up 38.4% After Strong Phase 3 Azetukalner Seizure Data And FDA Plans - Sahm
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering - GlobeNewswire
Xenon Pharmaceuticals announces pricing of upsized $650.0 million public offering - marketscreener.com
Xenon Pharmaceuticals Inc. Prices Upsized Public Offering, Anticipated Gross Proceeds of Approximately $650 Million - Quiver Quantitative
Xenon Pharmaceuticals prices $650M public offering at $57/share - Investing.com UK
Biotech Xenon raises $650M in stock sale at $57 a share - Stock Titan
Xenon Pharmaceuticals Announces Pricing Of Upsized $650.0 Million Public Offering - TradingView
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering - GlobeNewswire Inc.
[144] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study - Bitget
Xenon Pharmaceuticals announces proposed $500M public share offering - MSN
Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy - TipRanks
XENE: Wells Fargo Raises Price Target by 38.78% on Overweight Ra - GuruFocus
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE) - FinancialContent
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
XENE: Wedbush Raises Price Target for Xenon Pharmaceuticals | XE - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $64.00 at Wedbush - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - MarketBeat
XENE: HC Wainwright Raises Price Target for Xenon Pharmaceuticals | XENE Stock News - GuruFocus
Deutsche Bank Adjusts Xenon Pharmaceuticals PT to $90 From $56, Maintains Buy Rating - marketscreener.com
Xenon Pharmaceuticals stock reaches all-time high at 60.5 USD By Investing.com - Investing.com Canada
XENE Announces Positive Phase 3 Results for Epilepsy Treatment - GuruFocus
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):